People

I am a Radiochemist with experience in both SPECT and PET chemistry. Before I came to Glasgow, I worked for many years as both a radiochemist and a synthetic chemist in the radiopharmaceutical industry. My interests are using radiotracers to look at changes in biological chemistry in disease. As such, I’m interested in the development of novel radiotracers, which is a multi-disciplinary process bringing together chemistry, radiochemistry and biology, and the translation of such new tracers from a pre-clinical phase into the clinic. I’m also interested in the clinical applications of new and existing radiotracers, in which I collaborate with colleagues in Clinical Physics and Psychological Medicine. Beyond the development and use of tracers, I’m interested in the development of radiolabelling and purification methods

My scientific interest involves Molecular Imaging applied to oncology field. In particular, I support the use of PET imaging in order to evaluate and assess a tumour's stage and metabolism, and set up a proper therapeutic strategy.

Cancer research and development, drug discovery of antitumoral agents, targeted therapies, molecular imaging as innovative tool of diagnosis and treatment of brain tumours, medicinal chemistry of PARP inhibitors, radiochemistry, pre-clinical studies.

I am is a SINAPSE funded PET radiochemist who joined the Edinburgh CRIC (Clinical Research Imaging Centre) in July 2008. I graduated a PhD in Organic Chemistry in Grenoble, France, before being trained as a PET radiopharmaceutical chemist in Zurich (Switzerland). I am currently actively involved in the setting up of the Edinburgh radiochemistry suite where I will act as the Production Manager. I am particularly interested in the development of new radiotracers and the translation from R&D to human.

Dr Pimlott is the principal radiochemist in the research and development radiopharmaceutical group, based at the Radionuclide Dispensary, Western Infirmary, Glasgow. Her research is focused on the development of novel molecular imaging agents. This includes:-

• the development of novel radiolabelling methodologies
• the synthesis and evaluation of novel tracer candidates using both in vitro and in vivo imaging techniques
• the development of novel in vitro methodologies for the prediction of radiotracer in vivo characteristics.

Dr Pimlott is also experienced in the provision of radiopharmaceuticals for clinical research studies in compliance with Good Manufacturing Practice standards. Research is funded by the SINAPSE, Wellbeing of Women, Translational Medicine Research Collaboration (TMRC), Neurosciences Foundation, Chief Scientist Office (Scottish Executive), Medical Research Scotland and GE Healthcare.